When you build a clinic, it treats everything that walks through the door
For more than two decades, the United States' PEPFAR program has quietly woven itself into the fabric of life in some of the world's most vulnerable nations — not merely as an HIV intervention, but as a foundation for broader human flourishing. A May 2026 analysis by the Kaiser Family Foundation traces the program's reach through 2022, finding measurable improvements in overall mortality, maternal and child health, economic growth, and school enrollment in recipient countries. Now, as the Trump administration moves to cut funding, the question before policymakers is whether the architecture of progress built on a single disease mandate can survive the withdrawal of the hand that built it.
- PEPFAR's HIV infrastructure quietly became a lifeline for treating tuberculosis, malaria, and maternal illness — its true public health footprint far larger than AIDS statistics alone reveal.
- Economic growth accelerated and school enrollment rose in PEPFAR-supported countries, suggesting that a healthier workforce and stabilized communities created ripple effects across entire societies.
- COVID-19 delivered the same temporary shock to PEPFAR-recipient nations as to everyone else, but the program's underlying gains proved resilient — paused, not erased — signaling the durability of its investments.
- The Trump administration's planned funding cuts now threaten to unravel not just the HIV response but the collateral health, educational, and economic gains documented across more than a decade of data.
- With 26 million lives already saved and ongoing improvements at stake, advocates and researchers warn that defunding PEPFAR would impose costs measured not only in deaths, but in children leaving school and economies contracting.
The U.S. government's flagship HIV program has spent two decades doing something its architects may not have fully anticipated: saving lives from causes that have nothing to do with AIDS. A May 2026 analysis from the Kaiser Family Foundation extends earlier research through 2022, documenting how PEPFAR — the President's Emergency Plan for AIDS Relief — generated sweeping spillover benefits across health systems, economies, and schools in the countries where it operates.
Credited with saving 26 million lives since 2003, PEPFAR has maintained relatively stable funding for over a decade. The new KFF findings show its benefits continued expanding well beyond its original mandate. Overall mortality rates declined in recipient countries — not just AIDS deaths, but deaths from all causes. Maternal and child health indicators improved, as the clinics, health workers, and supply chains built to fight HIV became assets for treating other conditions entirely. The associations were significant enough to suggest that PEPFAR's true public health footprint is substantially larger than HIV statistics alone would indicate.
The economic and educational picture proved equally striking. PEPFAR-supported countries showed accelerated GDP per capita growth, and both girls and boys were more likely to remain in school. When COVID-19 struck in 2020, it disrupted these trends temporarily — but the KFF analysis found that recipient countries experienced the same pandemic shock as everyone else, suggesting the program's underlying gains were resilient rather than fragile.
The timing of the analysis carries particular weight. The Trump administration has announced plans to significantly reduce PEPFAR's funding, and KFF researchers warn that such cuts would likely reverse not only the HIV response but the collateral health, economic, and educational improvements their study documents. A country that has relied on PEPFAR-supported maternal health services for a decade would lose them. A child kept in school by economic stability tied to PEPFAR-linked employment would face renewed pressure to leave.
What the data ultimately reveals is that global health programs rarely operate in isolation. When a wealthy nation commits to fighting a single disease in poor countries, it builds capacity that serves many purposes — and the question now facing policymakers is whether those proven, measurable benefits will be preserved or sacrificed in the months ahead.
The U.S. government's flagship HIV program has been doing something unexpected for the past two decades: saving lives from causes that have nothing to do with AIDS. A new analysis from the Kaiser Family Foundation, released in May 2026, documents the ripple effects of PEPFAR—the President's Emergency Plan for AIDS Relief—across health systems, economies, and schools in the countries where it operates. The findings suggest that when the U.S. invested in fighting HIV in the developing world, it inadvertently strengthened entire health infrastructures, lifted economic growth, and kept children in classrooms.
PEPFAR, credited with saving 26 million lives since its launch in 2003, has maintained relatively stable funding levels for over a decade. Yet the new KFF research, which extends earlier analyses through 2022, shows the program's benefits have continued to expand well beyond its original mandate. The data reveals that PEPFAR investments correlate with measurable declines in overall mortality rates—not just AIDS deaths, but deaths from all causes. Maternal and child health indicators improved in recipient countries during the study period, suggesting that the health workers, clinics, and supply chains built to combat HIV became assets for treating other conditions. These weren't marginal gains. The associations were significant enough to indicate that PEPFAR's true public health footprint is substantially larger than HIV statistics alone would suggest.
The economic picture proved similarly striking. Countries receiving PEPFAR support showed accelerated GDP per capita growth rates compared to trends before the program's intervention. School enrollment figures shifted as well: both girls and boys were more likely to remain in school in PEPFAR-supported regions. These outcomes persisted even as global conditions deteriorated. When COVID-19 struck in 2020, it disrupted economies and forced school closures worldwide. But the KFF analysis found that PEPFAR-recipient countries experienced the same temporary pandemic shock as everyone else—suggesting that the program's underlying benefits proved resilient. The gains in economic growth and educational access did not evaporate; they were merely paused.
The timing of this analysis carries particular weight. The Trump administration has announced plans to significantly reduce PEPFAR's funding and scale back services in the coming years. The KFF researchers note that such cuts would likely reverse not only the HIV response but also the collateral health, economic, and educational improvements documented in their study. A country that has benefited from a decade of strengthened maternal health services, for instance, would lose access to those services if the clinics and personnel that provide them are defunded. A child kept in school by economic stability tied to PEPFAR-supported employment would face renewed pressure to leave. The analysis suggests the stakes extend far beyond the 26 million lives already saved—they encompass ongoing improvements in mortality, economic opportunity, and human development across multiple vulnerable populations.
What the KFF data ultimately reveals is that global health programs rarely operate in isolation. When a wealthy nation commits resources to fighting a single disease in poor countries, it builds capacity that serves many purposes. Clinics treat tuberculosis and malaria alongside HIV. Health workers trained in disease surveillance notice outbreaks of other illnesses. Economic activity generated by a healthier workforce benefits sectors unrelated to health. The question now facing policymakers is whether those collateral benefits—proven, measurable, and substantial—will be preserved or sacrificed as funding decisions are made in the months ahead.
Notable Quotes
PEPFAR investments were associated with significant improvements in all-cause mortality and maternal and child health measures, with positive spillover effects suggesting the program has had greater impact than for HIV alone— KFF analysis
More recent changes to the PEPFAR program, including significantly scaling back funding and services, could not only have negative impacts on the HIV response, but dampen improvements in other health areas— KFF analysis
The Hearth Conversation Another angle on the story
Why does it matter that PEPFAR's benefits extend beyond HIV? Isn't the program's core mission to fight AIDS?
The mission is HIV, yes, but the infrastructure built to deliver HIV care becomes the backbone of the entire health system. When you train a health worker to diagnose HIV, they can diagnose malaria. When you build a clinic network, it treats everything that walks through the door. The spillover effects aren't accidental—they're structural.
The analysis mentions COVID-19 caused temporary disruption. Does that mean PEPFAR protected countries from the pandemic's worst effects?
Not exactly. COVID hit everyone equally hard. But in PEPFAR countries, the underlying gains in mortality, economic growth, and school enrollment didn't collapse permanently. They dipped, then recovered. That resilience suggests the program had built something durable.
What happens if funding is cut as planned?
You lose the clinics, the trained workers, the supply chains. A country that spent fifteen years building maternal health capacity through PEPFAR-supported services would have to rebuild from scratch. The economic growth tied to a healthier workforce slows. Children pulled from school to work don't easily return.
Is there a way to measure what's at stake?
The data shows associations, not certainties. But when you see consistent improvements across mortality, GDP growth, and school enrollment in dozens of countries over nearly two decades, you're looking at something real. The question is whether policymakers believe the evidence enough to preserve it.
Who bears the cost if the cuts happen?
The people in those countries. The mothers who lose access to prenatal care. The children who leave school. The workers whose productivity declines as preventable diseases return. It's abstract in policy meetings, concrete on the ground.